title: Local administration of methotrexate bound to activated carbon particles (MTX-CH) for treating cancers in mice.
abstract: OBJECTIVE
  A new dosage formulation of methotrexate (MTX-CH) was developed to control cancer growth by local administration.
  
  
  METHODS
  BALB/c mice received a subcutaneous inoculation with transplantable Colon 26 cancer cells on the back. When cancerous tumor became 7 mm in diameter, MTX-CH or MTX aqueous solution (MTX-sol) was injected into the tumor. The MTX concentration in the tumor was compared between the MTX-CH group and the MTX-sol group. The tumor growth was assessed in single or repeated local administration experiments.
  
  
  RESULTS
  The MTX concentrations were significantly higher for longer periods in the MTX-CH group than those in the MTX-sol group. Repeated MTX-CH administration was significantly more effective for suppressing the tumor growth compared with repeated MTX-sol administration.
  
  
  CONCLUSIONS
  MTX-CH is superior to MTX-sol in controlling the tumor growth by local administration because of its long-acting effect.
authors.affiliation: Department of Digestive Surgery, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan 602-8566. titoh@frontier.kyoto-u.ac.jp
authors.forename: Tadao
authors.initials: T
authors.lastname: Ito
authors.forename: Akeo
authors.initials: A
authors.lastname: Hagiwara
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takagi
authors.forename: Junshin
authors.initials: J
authors.lastname: Fujiyama
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Sonoyama
authors.forename: Katsumi
authors.initials: K
authors.lastname: Shimomura
authors.forename: Manabu
authors.initials: M
authors.lastname: Takemura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Toma
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kin
authors.forename: Yuen
authors.initials: Y
authors.lastname: Nakase
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Yamagishi
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002606:Charcoal / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000473:pathology; D004334:Drug Administration Schedule; D004337:Drug Carriers; D004354:Drug Screening Assays, Antitumor; D015552:Injections, Intralesional; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010316:Particle Size; D011205:Povidone / Q000008:administration & dosage; D012996:Solutions; D014407:Tumor Cells, Cultured / Q000637:transplantation
chemical_list: D000964:Antimetabolites, Antineoplastic; D004337:Drug Carriers; D012996:Solutions; D002606:Charcoal; D011205:Povidone; D008727:Methotrexate